{"id":"https://openalex.org/W1900569402","doi":"https://doi.org/10.1212/wnl.84.14_supplement.p3.191","title":"Comparative Cognitive Effects of Lacosamide versus Carbamazepine (P3.191)","display_name":"Comparative Cognitive Effects of Lacosamide versus Carbamazepine (P3.191)","publication_year":2015,"publication_date":"2015-04-06","ids":{"openalex":"https://openalex.org/W1900569402","doi":"https://doi.org/10.1212/wnl.84.14_supplement.p3.191","mag":"1900569402"},"language":"en","primary_location":{"id":"doi:10.1212/wnl.84.14_supplement.p3.191","doi":"https://doi.org/10.1212/wnl.84.14_supplement.p3.191","is_oa":false,"landing_page_url":"http://dx.doi.org/10.1212/wnl.84.14_supplement.p3.191","pdf_url":null,"source":{"id":"https://openalex.org/S79704628","display_name":"Neurology","issn_l":"0028-3878","issn":["0028-3878","1526-632X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neurology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5088890091","display_name":"David W. Loring","orcid":"https://orcid.org/0000-0003-2497-1074","observed_orcids":["https://orcid.org/0000-0003-2497-1074"]},"institutions":[{"id":"https://openalex.org/I150468666","display_name":"Emory University","ror":"https://ror.org/03czfpz43","country_code":"US","type":"education","lineage":["https://openalex.org/I150468666"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David Loring","raw_affiliation_strings":["Emory University Atlanta GA United States","2Emory University Atlanta GA United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Emory University Atlanta GA United States","institution_ids":["https://openalex.org/I150468666"]},{"raw_affiliation_string":"2Emory University Atlanta GA United States","institution_ids":["https://openalex.org/I150468666"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028839905","display_name":"Kimford J. Meador","orcid":"https://orcid.org/0000-0002-7471-882X","observed_orcids":["https://orcid.org/0000-0002-7471-882X"]},"institutions":[{"id":"https://openalex.org/I4210137306","display_name":"Stanford Medicine","ror":"https://ror.org/03mtd9a03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210137306","https://openalex.org/I97018004"]},{"id":"https://openalex.org/I97018004","display_name":"Stanford University","ror":"https://ror.org/00f54p054","country_code":"US","type":"education","lineage":["https://openalex.org/I97018004"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kimford Meador","raw_affiliation_strings":["Stanford University School of Medicine Stanford CA United States","3Stanford University School of Medicine Stanford CA United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Stanford University School of Medicine Stanford CA United States","institution_ids":["https://openalex.org/I4210137306","https://openalex.org/I97018004"]},{"raw_affiliation_string":"3Stanford University School of Medicine Stanford CA United States","institution_ids":["https://openalex.org/I4210137306","https://openalex.org/I97018004"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Alan Boyd","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Alan Boyd","raw_affiliation_strings":["CNS Vital Signs Chapel Hill NC United States","1CNS Vital Signs Chapel Hill NC United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"CNS Vital Signs Chapel Hill NC United States","institution_ids":[]},{"raw_affiliation_string":"1CNS Vital Signs Chapel Hill NC United States","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5081668363","display_name":"William Byrnes","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"William Byrnes","raw_affiliation_strings":["UCB Pharma Raleigh NC United States","5UCB Pharma Raleigh NC United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UCB Pharma Raleigh NC United States","institution_ids":[]},{"raw_affiliation_string":"5UCB Pharma Raleigh NC United States","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5038291890","display_name":"Deanne Dilley","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Deanne Dilley","raw_affiliation_strings":["UCB Pharma Raleigh NC United States","5UCB Pharma Raleigh NC United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UCB Pharma Raleigh NC United States","institution_ids":[]},{"raw_affiliation_string":"5UCB Pharma Raleigh NC United States","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5079889841","display_name":"Simon Borghs","orcid":"https://orcid.org/0000-0003-1081-7981","observed_orcids":["https://orcid.org/0000-0003-1081-7981"]},"institutions":[{"id":"https://openalex.org/I4210134054","display_name":"UCB Pharma (United Kingdom)","ror":"https://ror.org/03428qp74","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210134054","https://openalex.org/I85722119"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Simon Borghs","raw_affiliation_strings":["UCB Pharma Slough  United Kingdom","6UCB Pharma Slough United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UCB Pharma Slough  United Kingdom","institution_ids":["https://openalex.org/I4210134054"]},{"raw_affiliation_string":"6UCB Pharma Slough United Kingdom","institution_ids":["https://openalex.org/I4210134054"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110744006","display_name":"Marc De Backer","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I85722119","display_name":"UCB Pharma (Belgium)","ror":"https://ror.org/01n029866","country_code":"BE","type":"company","lineage":["https://openalex.org/I85722119"]}],"countries":["BE"],"is_corresponding":false,"raw_author_name":"Marc De Backer","raw_affiliation_strings":["UCB Pharma SA Brussels  Belgium","8UCB Pharma SA Brussels Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UCB Pharma SA Brussels  Belgium","institution_ids":["https://openalex.org/I85722119"]},{"raw_affiliation_string":"8UCB Pharma SA Brussels Belgium","institution_ids":["https://openalex.org/I85722119"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5023000375","display_name":"Tyler J. Story","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210127098","display_name":"UCB Pharma (United States)","ror":"https://ror.org/028qka468","country_code":"US","type":"company","lineage":["https://openalex.org/I4210127098","https://openalex.org/I85722119"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Tyler Story","raw_affiliation_strings":["UCB Pharma Smyrna GA United States","7UCB Pharma Smyrna GA United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UCB Pharma Smyrna GA United States","institution_ids":["https://openalex.org/I4210127098"]},{"raw_affiliation_string":"7UCB Pharma Smyrna GA United States","institution_ids":["https://openalex.org/I4210127098"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5091904487","display_name":"Peter Dedeken","orcid":"https://orcid.org/0000-0001-8493-6276","observed_orcids":["https://orcid.org/0000-0001-8493-6276"]},"institutions":[{"id":"https://openalex.org/I85722119","display_name":"UCB Pharma (Belgium)","ror":"https://ror.org/01n029866","country_code":"BE","type":"company","lineage":["https://openalex.org/I85722119"]}],"countries":["BE"],"is_corresponding":false,"raw_author_name":"Peter Dedeken","raw_affiliation_strings":["UCB Pharma Brussels  Belgium","4UCB Pharma Brussels Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UCB Pharma Brussels  Belgium","institution_ids":["https://openalex.org/I85722119"]},{"raw_affiliation_string":"4UCB Pharma Brussels Belgium","institution_ids":["https://openalex.org/I85722119"]}]},{"author_position":"last","author":{"id":null,"display_name":"Elizabeth Webster","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Elizabeth Webster","raw_affiliation_strings":["UCB Pharma Raleigh NC United States","5UCB Pharma Raleigh NC United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UCB Pharma Raleigh NC United States","institution_ids":[]},{"raw_affiliation_string":"5UCB Pharma Raleigh NC United States","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":3,"institutions_distinct_count":6,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.07122916,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"84","issue":"14_supplement","first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10094","display_name":"Epilepsy research and treatment","score":0.7476000189781189,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10094","display_name":"Epilepsy research and treatment","score":0.7476000189781189,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12229","display_name":"Pharmacological Effects and Toxicity Studies","score":0.23600000143051147,"subfield":{"id":"https://openalex.org/subfields/2735","display_name":"Pediatrics, Perinatology and Child Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11117","display_name":"Drug-Induced Adverse Reactions","score":0.0010999999940395355,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/lacosamide","display_name":"lacosamide","score":0.9950000047683716},{"id":"https://openalex.org/keywords/carbamazepine","display_name":"carbamazepine","score":0.9430000185966492},{"id":"https://openalex.org/keywords/antiepileptic-drugs","display_name":"antiepileptic drugs","score":0.9599999785423279},{"id":"https://openalex.org/keywords/cognitive-effects","display_name":"cognitive effects","score":0.9150000214576721},{"id":"https://openalex.org/keywords/neuropsychological-outcomes","display_name":"neuropsychological outcomes","score":0.7250000238418579},{"id":"https://openalex.org/keywords/electroencephalography","display_name":"EEG","score":0.5580000281333923},{"id":"https://openalex.org/keywords/p300-latency","display_name":"P300 latency","score":0.8849999904632568},{"id":"https://openalex.org/keywords/drug-tolerability","display_name":"drug tolerability","score":0.6620000004768372},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.875},{"id":"https://openalex.org/keywords/healthy-volunteers","display_name":"healthy volunteers","score":0.5429999828338623},{"id":"https://openalex.org/keywords/psychomotor-speed","display_name":"psychomotor speed","score":0.7049999833106995},{"id":"https://openalex.org/keywords/executive-function","display_name":"executive function","score":0.6610000133514404},{"id":"https://openalex.org/keywords/memory","display_name":"memory","score":0.8309999704360962},{"id":"https://openalex.org/keywords/attention","display_name":"attention","score":0.8930000066757202},{"id":"https://openalex.org/keywords/medication-discontinuation","display_name":"drug discontinuation","score":0.515999972820282},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.5770000219345093},{"id":"https://openalex.org/keywords/drug-efficacy","display_name":"drug efficacy","score":0.3449999988079071},{"id":"https://openalex.org/keywords/epilepsy-treatment","display_name":"epilepsy treatment","score":0.35600000619888306}],"concepts":[{"id":"https://openalex.org/C2778139780","wikidata":"https://www.wikidata.org/wiki/Q420077","display_name":"Lacosamide","level":3,"score":0.985297441482544},{"id":"https://openalex.org/C2779253243","wikidata":"https://www.wikidata.org/wiki/Q410412","display_name":"Carbamazepine","level":3,"score":0.8043334484100342},{"id":"https://openalex.org/C169900460","wikidata":"https://www.wikidata.org/wiki/Q2200417","display_name":"Cognition","level":2,"score":0.4598331153392792},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.42836302518844604},{"id":"https://openalex.org/C169760540","wikidata":"https://www.wikidata.org/wiki/Q207011","display_name":"Neuroscience","level":1,"score":0.3393549621105194},{"id":"https://openalex.org/C15744967","wikidata":"https://www.wikidata.org/wiki/Q9418","display_name":"Psychology","level":0,"score":0.3200392425060272},{"id":"https://openalex.org/C2778186239","wikidata":"https://www.wikidata.org/wiki/Q41571","display_name":"Epilepsy","level":2,"score":0.24551314115524292}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1212/wnl.84.14_supplement.p3.191","doi":"https://doi.org/10.1212/wnl.84.14_supplement.p3.191","is_oa":false,"landing_page_url":"http://dx.doi.org/10.1212/wnl.84.14_supplement.p3.191","pdf_url":null,"source":{"id":"https://openalex.org/S79704628","display_name":"Neurology","issn_l":"0028-3878","issn":["0028-3878","1526-632X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neurology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2518080042","https://openalex.org/W2792950270","https://openalex.org/W2014853652","https://openalex.org/W3107520175","https://openalex.org/W2084873896","https://openalex.org/W2384146088","https://openalex.org/W2044642402","https://openalex.org/W3160302372","https://openalex.org/W2981112956","https://openalex.org/W2166522334"],"abstract_inverted_index":{"OBJECTIVE:To":[0],"evaluate":[1],"cognitive":[2,102,172,285],"and":[3,36,52,59,81,104,114,129,188,211,228,239,252,255,258,278],"EEG":[4,53,215,253],"effects":[5,29,54,163,254],"of":[6,16,30,38,55,73,83,121,194,207,224],"lacosamide":[7],"(LCM)":[8],"compared":[9,166,180,287],"to":[10,167,181,245,288],"carbamazepine":[11],"immediate-release":[12],"(CBZ-IR).":[13],"BACKGROUND:Differential":[14],"effectiveness":[15],"antiepileptic":[17],"drugs":[18],"(AEDs)":[19],"is":[20],"more":[21],"commonly":[22],"determined":[23],"by":[24],"tolerability":[25,35],"than":[26,202,261],"efficacy.":[27],"Cognitive":[28],"AEDs":[31],"can":[32],"adversely":[33],"affect":[34],"quality":[37],"life.":[39],"DESIGN/METHODS:Randomized,":[40],"double-blind,":[41],"double-dummy,":[42],"two-period":[43],"crossover":[44],"study":[45],"(NCT01530022)":[46],"in":[47,263],"healthy":[48,134,264],"controls":[49],"comparing":[50],"neuropsychological":[51,106,209,251],"LCM":[56,168,203,227,238,248,281],"(150mg":[57],"bid)":[58],"CBZ-IR":[60,165,187,198,231,241,262],"(300mg":[61],"bid,":[62],"immediate":[63],"release).":[64],"Testing":[65],"was":[66,94,199],"conducted":[67],"at":[68],"screening,":[69],"pre-drug":[70],"baseline,":[71],"end":[72,82],"each":[74,84],"treatment":[75,147],"period":[76,86],"(3-week":[77],"titration;":[78],"3-week":[79],"maintenance),":[80],"washout":[85],"(4":[87],"weeks":[88],"after":[89],"treatment).":[90],"A":[91],"composite":[92,123],"Z-score":[93,178],"derived":[95],"for":[96,164,169,186,190,204,214,270],"the":[97,122,170,208],"primary":[98,150,171],"outcome":[99,173],"variable":[100],"(computerized":[101],"tests":[103],"traditional":[105],"paper/pencil":[107],"measures,":[108,126],"evaluating":[109],"attention,":[110],"speed,":[111,274],"executive":[112],"functions,":[113],"memory).":[115],"Other":[116],"variables":[117,196,210],"included":[118,152],"individual":[119,195],"subcomponents":[120],"score,":[124],"EEG/EP":[125],"safety":[127],"variables,":[128],"pharmacokinetic":[130],"data.":[131],"RESULTS:":[132],"60":[133],"adults":[135],"enrolled":[136],"(57[percnt]":[137],"female,":[138],"mean":[139],"age":[140],"34y":[141],"[SD":[142,175],"10.5]);":[143],"44":[144],"completed":[145],"both":[146],"periods.":[148],"The":[149],"analysis":[151],"41":[153],"per":[154],"protocol":[155],"subjects.":[156,265],"Wilcoxon":[157],"rank":[158],"sum":[159],"test":[160],"revealed":[161,197],"worse":[162,201],"(0.33":[174],"1.36],":[176],"p=0.01).":[177],"differences":[179,267],"non-drug":[182],"conditions":[183],"were":[184,268],"-0.26":[185],"+0.08":[189],"LCM.":[191],"Secondary":[192],"analyses":[193],"statistically":[200],"25[percnt]":[205],"(4/16)":[206],"20[percnt]":[212],"(1/5)":[213],"measures":[216],"(i.e.,":[217],"P3":[218,279],"latency);":[219],"none":[220],"favored":[221],"CBZ-IR.":[222,289],"22[percnt]":[223],"subjects":[225,242],"receiving":[226,230],"49[percnt]":[229],"had":[232,249],"drug-related":[233],"adverse":[234],"events":[235],"(AEs);":[236],"2":[237],"8":[240],"discontinued":[243],"due":[244],"AEs.":[246],"CONCLUSIONS:":[247],"fewer":[250,256],"AEs":[257],"AE-related":[259],"discontinuations":[260],"Significant":[266],"observed":[269],"dual":[271],"processing,":[272],"psychomotor":[273],"perceived":[275],"drug":[276],"effects,":[277],"latency.":[280],"exhibits":[282],"a":[283],"favorable":[284],"profile":[286],"Study":[290],"Supported":[291],"by:UCB":[292],"Pharma":[293]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}